A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients
Part of paid clinical trials in Mobile, Alabama.
- Sponsor
- Glaxo Wellcome
- Study ID
- NCT00002000
- Status
- Completed
Conditions
- HIV Infections
- Herpes Simplex
Eligibility Criteria
- Sex
- ALL
- Age
- 13 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Valacyclovir hydrochloride — DRUG
- Acyclovir — DRUG
Study Details
To evaluate the safety and efficacy of oral valacyclovir hydrochloride (256U87) vs. acyclovir in the treatment of recurrent anogenital herpes in HIV-infected patients (CD4 greater than or equal to 100).
Key Dates
- Status verified
- Apr 1996
Study Design
- Primary purpose
- TREATMENT
Locations (22)
Find similar trials in Mobile, AL
By condition
By specialty
Related Studies
- SCOPE: Observational Study of the Consequences of the Protease Inhibitor EraRecruiting · University of California, San Francisco · San Francisco, California
- Imaging Immune Activation in HIV by PET-MRPHASE2 · Recruiting · CellSight Technologies, Inc. · San Francisco, California
- HIV Prevention Among At-risk Latinos in the HeartlandEnrolling By Invitation · Medical College of Wisconsin · Indianapolis, Indiana
- HIV Treatment Adherence Dose Determination TrialRecruiting · University of Connecticut · Storrs, Connecticut